Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease
Fecha
2023-09-25Autor
Bagán, Andrea
Rodriguez-Arévalo, Sergio
Taboada-Jara, Teresa
Griñán-Ferré, Christian
Pallàs, Mercè
Brocos Mosquera, Iria
Morales-García, José A.
Pérez, Belén
Diaz, Caridad
Fernández-Godino, Rosario
Genilloud, Olga
Beljkas, Milan
Oljacic, Slavica
Nikolic, Katarina
Escolano, Carmen
Metadatos
Mostrar el registro completo del ítem
Pharmaceutics 15(10) : (2023) // Article ID 2381
Resumen
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer’s disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson’s disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Colecciones
Excepto si se señala otra cosa, la licencia del ítem se describe como © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).